Low-Dose Metformin Reprograms the Tumor Immune Microenvironment in Human Esophageal Cancer: Results of a Phase II Clinical Trial.
Wang S, Lin Y, Xiong X, Wang L, Guo Y, Chen Y, Chen S, Wang G, Lin P, Chen H, Yeung SJ, Bremer E, Zhang H.
Wang S, et al. Among authors: chen s, chen h, chen y.
Clin Cancer Res. 2020 Sep 15;26(18):4921-4932. doi: 10.1158/1078-0432.CCR-20-0113. Epub 2020 Jul 9.
Clin Cancer Res. 2020.
PMID: 32646922
Clinical Trial.